Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

LA JOLLA PHARMACEUTICAL CO Form 4 April 18, 2006 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations Filed pursuant to 3 Section 17(a) of the	NERSHIP OF NERSHIP OF NERSHIP OF NUMBER: 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5	
may continue.	of the Investment Company Act of 194	
(Print or Type Responses)		
1. Name and Address of Reporting Person <u>*</u> JENN PAUL	2. Issuer Name and Ticker or Trading Symbol LA JOLLA PHARMACEUTICAL CO [LJPC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) (Middle) 6455 NANCY RIDGE DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 04/17/2006	Director 10% Owner X Officer (give title Other (specify below) VP of Product Development
(Street) SAN DIEGO, CA 92121	4. If Amendment, Date Original Filed(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - Non-Derivative Securities Acq	uired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Dee Execution any (Month/	1	5. Amount of Securities6. Ownership Form: Direct7. Nature of IndirectBeneficially Owned(D) orBeneficialOwnedIndirect (I) Indirect (I)Ownership OwnershipFollowing Transaction(s) (Instr. 3 and 4)(Instr. 4)
Common 03/31/2006 Stock	$J_{(1)}^{(1)}$ 174 A $\frac{$}{3.06}$	14,801 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5))		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 4.46	04/17/2006		A	122,548	(2)	04/17/2016	Common Stock	122,548

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
JENN PAUL 6455 NANCY RIDGE DRIVE SAN DIEGO, CA 92121			VP of Product Development			
Signatures						
/s/ Gail A. Sloan Attorney-in-fac Jenn	ct for Pau	1 C.	04/18/2006			
<u>**</u> Signature of Reporting Pers	on		Date			
Explanation of Responses:						

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Acquired pursuant to the Company?s Employee Stock Purchase Plan.

(2) The stock options vest and become exercisable monthly over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.